Relay Therapeutics (RLAY) Share-based Compensation (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Share-based Compensation of $10.5 million for Q1 2026, down 45.47% year-over-year from $19.3 million in Q1 2025, and up 124.83% quarter-over-quarter from -$42.4 million in Q4 2025.
Relay Therapeutics (RLAY) Share-based Compensation (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Share-based Compensation for 8 consecutive years, with $10.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 45.47% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at -$13.1 million (down 120.53% YoY), while the FY2025 annual figure was $27.6 million, down 70.68% from the prior year.
- Share-based Compensation advanced to $10.5 million in Q1 2026 per RLAY's latest filing, from -$42.4 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $27.2 million in Q1 2024 and bottomed at -$42.4 million in Q4 2025.
- Historically, Share-based Compensation has averaged $12.7 million across 5 years, with a median of $15.1 million in 2022.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 692.67% — and 2025, when it plunged 340.68%.
- Relay Therapeutics' Share-based Compensation stood at $9.5 million in 2022, then jumped by 102.55% to $19.3 million in 2023, then fell by 8.47% to $17.6 million in 2024, then sank by 340.68% to -$42.4 million in 2025, then surged by 124.83% to $10.5 million in 2026.
- Business Quant data shows RLAY's Share-based Compensation at $10.5 million in Q1 2026, -$42.4 million in Q4 2025, and $9.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | 5.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.84 Mn |
| Jun 30, 2026 | 5.84 Mn |
| Mar 31, 2026 | 10.54 Mn |
| Mar 31, 2026 | 10.54 Mn |
| Dec 31, 2025 | -42.44 Mn |
| Dec 31, 2025 | -42.44 Mn |
| Sep 30, 2025 | 9.53 Mn |
| Sep 30, 2025 | 9.53 Mn |
| Jun 30, 2025 | 9.31 Mn |
| Jun 30, 2025 | 9.31 Mn |
| Mar 31, 2025 | 19.33 Mn |
| Mar 31, 2025 | 19.33 Mn |
| Dec 31, 2024 | 17.64 Mn |
| Dec 31, 2024 | 17.64 Mn |
| Sep 30, 2024 | 11.08 Mn |
| Sep 30, 2024 | 11.08 Mn |
| Jun 30, 2024 | 15.62 Mn |
| Jun 30, 2024 | 15.62 Mn |
| Mar 31, 2024 | 27.19 Mn |
| Mar 31, 2024 | 27.19 Mn |